RACHEL CRAWFORD: Open Payments
NPI 1598490377 · TUSCALOOSA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$824 in 44 payments from 13 companies in 2025. Trend: 2023 $151 · 2024 $633 · 2025 $824
Food & beverage: $824
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $290 |
| AstraZeneca Pharmaceuticals LP | 5 | $80 |
| Corium, LLC | 4 | $74 |
| Novo Nordisk Inc | 4 | $72 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $69 |
| Novartis Pharmaceuticals Corporation | 3 | $68 |
| GlaxoSmithKline, LLC. | 2 | $43 |
| Collegium Pharmaceutical, Inc. | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Lundbeck LLC | 1 | $23 |
Products named: VRAYLAR, Azstarys, CAPLYTA, LEQVIO, AIRSUPRA, UBRELVY, REXULTI, QULIPTA.
Industry payments across AL — which companies pay providers there.
